Biogen Idec (BIIB) Up On Renewed Takeover Speculation
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Join SI Premium – FREE
Shares of Biogen Idec Inc. (Nasdaq: BIIB) are seeing interest today on renewed takeover speculation. Shares are up 1.8 percent to $58.23 on solid volume and option activity.
Biogen Idec has been unsuccessful in M&A recently. In 2007, Biogen unsuccessfully attempted to sell itself. In 2009, the company unsuccessfully tried to takeover Facet Biotech (Nasdaq: FACT).
Investors are hoping the recent spate of bad news in M&A for Biogen will reverse. With activist investor Carl Icahn involved with the stock, investors may not have to be hoping to long.
Biogen Idec has been unsuccessful in M&A recently. In 2007, Biogen unsuccessfully attempted to sell itself. In 2009, the company unsuccessfully tried to takeover Facet Biotech (Nasdaq: FACT).
Investors are hoping the recent spate of bad news in M&A for Biogen will reverse. With activist investor Carl Icahn involved with the stock, investors may not have to be hoping to long.
You May Also Be Interested In
- Biogen's Empaveli cuts proteinuria 75% in teens with rare kidney disease
- SEC Issues Guidance to Tokenize Stocks After Clarity Act Failure, Robinhood (HOOD) Gains
- Caesars Entertainment receives FTC request on Fertitta deal
Create E-mail Alert Related Categories
Insiders' Blog, RumorsRelated Entities
Carl IcahnSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
